Recent signs seem to indicate that the markets have begun to heal, but Luke Bergstrom isn’t ready to pinpoint any lasting trends in deal making.
The Silicon Valley partner at Latham & Watkins says the $440 million sale of client VNUS Medical Technologies Inc. to publicly traded Covidien is indicative only of the tenet that cash-rich strategic buyers can push a deal through even in the worst of times.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
